Omega-3 (DHA/EPA) for Alzheimer's Disease
Also known as: DHA, EPA, Fish oil, Docosahexaenoic acid, Eicosapentaenoic acid
DHA is critical for synaptic membrane structure, and its depletion correlates with cognitive decline and Alzheimer's progression.
Mechanism of Action
DHA maintains synaptic membrane fluidity essential for neurotransmitter receptor function. It generates neuroprotectin D1 (NPD1) which inhibits amyloid-beta secretion and promotes neuronal survival. EPA reduces neuroinflammatory cytokines through SPM generation.
General mechanism: Essential fatty acids. Neuronal membrane component, SPM precursor, NF-κB inhibitor, anti-cachexia, BDNF enhancer.
Current Evidence
Epidemiological studies show higher DHA intake reduces AD risk by 40-50%. ADCS-DHA trial in mild-moderate AD was negative, but pre-dementia supplementation may be more effective. APOEε4 carriers may need higher doses.
Clinical Status: Epidemiological support strong. Clinical trials mixed. Prevention focus preferred.
Safety Profile
Very safe. Fishy aftertaste. Mild GI effects. Bleeding risk at very high doses. Monitor with anticoagulants.
Key Research Questions
- Is DHA supplementation protective only before AD onset?
- Do APOE4 carriers need higher DHA doses for neuroprotection?